Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage

Journal of Hypertension

Volumn 29, Issue 8, 2011, Pages 1602-1612

  Knier, Benjamin ^a   Cordasic, Nada ^a   Klanke, Bernd ^a   Heusinger Ribeiro, Juliane ^a   Daniel, Christoph ^a   Veelken, Roland ^a   Hartner, Andrea ^a   Hilgers, Karl F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

blood pressure; cardiac fibrosis; glomerular injury; metalloproteinases; renin angiotensin system; tubulointerstitial fibrosis

Indexed keywords

ANGIOTENSIN II; GELATINASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; GLOMERULOSCLEROSIS; HEART INJURY; HEART MUSCLE; HEART MUSCLE FIBROSIS; HISTOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY INJURY; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; TELEMETRY; WILD TYPE; ZYMOGRAPHY;

EID: 79960580979     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834840e8     Document Type: Article

References (32)

1. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 2006; 70:1914-1919. (Pubitemid 44863378)
2. Sappino AP, Huarte J, Vassalli JD, Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 1991; 87:962-970.
3. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996; 148:1345-1350.
4. Mignatti P. Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int Suppl 1995; 49:S12-S14.
5. Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 2009; 5:203-211.
6. Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 2006; 281:2120-2127. (Pubitemid 43845801)
7. Hu K, Wu C, Mars WM, Liu Y. Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling. J Clin Invest 2007; 117:3821-3832. (Pubitemid 350224092)
8. Hu K, Lin L, Tan X, Yang J, Bu G, Mars WM, Liu Y. TPA protects renal interstitial fibroblasts and myofibroblasts from apoptosis. J Am Soc Nephrol 2008; 19:503-514. (Pubitemid 351355394)
9. Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004; 279:22595-22604. (Pubitemid 38679460)
10. Zhang G, Eddy AA. Urokinase and its receptors in chronic kidney disease. Front Biosci 2008; 13:5462-5478.
11. Haraguchi M, Border WA, Huang Y, Noble NA. T-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int 2001; 59:2146-2155. (Pubitemid 32467606)
12. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosteroneinduced glomerular injury. Kidney Int 2006; 69:1064-1072. (Pubitemid 43372182)
13. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 2005; 67:1297-1307. (Pubitemid 40463106)
14. Zhang G, Kernan KA, Collins SJ, Cai X, Lopez-Guisa JM, Degen JL, et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-tomesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol 2007; 18:846-859. (Pubitemid 46434501)
15. Edgtton KL, Gow RM, Kelly DJ, Carmeliet P, Kitching AR. Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int 2004; 66:68-76. (Pubitemid 38870083)
16. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 2004; 95:637-644. (Pubitemid 39274379)
17. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17:2999-3012. (Pubitemid 44707760)
18. Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106:1341-1350.
19. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001; 60:587-596. (Pubitemid 32678902)
20. Wang H, Zhang Y, Heuckeroth RO. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett 2007; 581:3098-3104. (Pubitemid 46899037)
21. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002; 110:1525-1538. (Pubitemid 35396923)
22. Cao C, Lawrence DA, Li Y, Von Arnim CA, Herz J, Su EJ, et al. Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J 2006; 25:1860-1870.
23. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood 1998; 91:2005-2009. (Pubitemid 28185501)
24. Yee JA, Yan L, Dominguez JC, Allan EH, Martin TJ. Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. J Cell Physiol 1993; 157:528-534. (Pubitemid 23361181)
25. Hu K, Mars WM, Liu Y. Novel actions of tissue-type plasminogen activator in chronic kidney disease. Front Biosci 2008; 13:5174-5186. (Pubitemid 351599667)
26. Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 2005; 25:365-371. (Pubitemid 40189159)
27. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 99:3063-3070. (Pubitemid 29270438)
28. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106:55-62. (Pubitemid 30437240)
29. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003; 285:H1229-H1235. (Pubitemid 37048181)
30. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001; 103:2303-2309. (Pubitemid 32433722)
31. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89:201-210. (Pubitemid 34132679)
32. Xu Z, Castellino FJ, Ploplis VA. Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture. Blood 2010; 115:2038-2047.